leadf
logo-loader
viewAnteris Technologies Ltd

Admedus begins anti-calcification comparison study for ADAPT®

The aim of this study is to evaluate anti-calcification properties in the established subcutaneous rat model.

Admedus Ltd - Admedus begins anti-calcification preclinical trial
The study will be conducted in Minneapolis, USA, at a world-renowned preclinical facility

Admedus Ltd (ASX:AHZ) has begun a preclinical study which will compare anti-calcification properties of its proprietary ADAPT® treated tissue with other bovine and porcine tissues used in commercially available SAVR and TAVR valves.

Calcification plays a significant role in the failure of bioprosthetic and other tissue heart valve substitutes.

The study will be conducted in Minneapolis, USA, at a world-renowned preclinical facility with the aim being to evaluate anti-calcification properties in the established subcutaneous rat model.

Around 48 rats will be implanted and harvested implants will be processed for histological and calcium/phosphorus analysis initially at the end of four months.

Step towards commercialisation

Chief executive officer Wayne Paterson said: “Collecting and building data proving superiority of ADAPT® tissue against current treatments in the TAVR market is an important step towards ultimate commercialisation.

“Such data builds a positive benefit-risk profile for new ADAPT® treated tissue products, for which regulatory initiatives may reveal a fast path to market.”

Second patient implanted in SAVR trial

Earlier this month Admedus implanted an ADAPT® treated DurAVR™ 3D single-piece aortic valve in a second patient at the University Hospitals Leuven, Belgium, in its first-in-human surgical aortic valve replacement (SAVR) study.

The first patient was implanted in April and Admedus chief executive officer Wayne Paterson said both patients were recovering well.

He said: “The first patient, implanted with DurAVR™ 3D single-piece aortic valve on March 26, 2020, is doing well, over a month post-implantation and patient two is recovering as expected.

“Given the challenges that the COVID-19 pandemic is presenting for hospitals, it is encouraging to see the second surgery completed.

“We are grateful to the surgeon and the patient for undergoing the procedure.”

Fifteen patients are to be enrolled in the study and followed up for six months after implantation.

Share have been as much as 2.5% higher to $7.50 intra-day.

Quick facts: Anteris Technologies Ltd

Price: 3.99 AUD

ASX:AVR
Market: ASX
Market Cap: $23.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Anteris Technologies CEO hails 'very good results' from DurAVR™ human study

Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson caught up with Proactive's Andrew Scott soon after reporting that early results from its first-in-human study of its proprietary DurAVR™ aortic valve found that patient outcomes exceeded the results of what is normally expected following a...

5 days, 7 hours ago

2 min read